Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Natasha B. Leighl, Ray D. Page, Victoria M. Raymond et al. · Clinical Cancer Research · 2019 · 597 citations · Full text

Medicine, Genetics, Oncology +17

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey et al. · Clinical Cancer Research · 2015 · 548 citations · Full text

Medicine, Oncology, Pharmacology +14

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Zhe Yang, Nong Yang, Qiuxiang Ou et al. · Clinical Cancer Research · 2018 · 544 citations

Medicine, Oncology, Pharmacology +17

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology · 2020 · 413 citations · Full text

Medicine, Oncology, Pharmacology +15